Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
about
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxisIndividualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demandHereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie LectureSafety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970sRecombinant factor VIII in the management of hemophilia A: current use and future promise.Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia.Health technology assessment and haemophilia.Haemophilia prophylaxis: how can we justify the costs?Tertiary prophylaxis in adults: is there a rationale?Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.Making economic evaluations more helpful for treatment choices in haemophilia.Personalized prophylaxis in people with hemophilia A: challenges and achievements.Health economic models in hemophilia A and utility assumptions from a clinician's perspective.A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries.Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries.Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions.Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress. Understanding health outcomes: focus on haemophilia.Gene therapy in hemophilia A: a cost-effectiveness analysis
P2860
Q26865814-FFBCB312-4A68-4CAE-9AA1-7030184FAB99Q28075208-B4C96F88-6A71-4248-A271-A2292FB5D4AAQ28082558-A2F9059E-EA7B-43F7-A445-F9DD22E3B627Q28742240-A78E47E7-8049-4343-963B-21112B1C94CAQ30539596-76F0A353-B7D7-4B94-9AC0-1F26ADDD8BB1Q33715399-B2F85E3F-55EA-4518-9F7B-47983F01FE70Q34890523-0CAC1083-4863-4FA9-A71E-5DE103A21894Q37098836-D85D0EF7-D9C8-4669-8489-DEA383D0BAE8Q37230340-30399648-0112-450C-9055-41FFA338A26EQ37845930-D14C5045-4E6E-4D33-A5F2-0D89AC3985FCQ37984093-C2C562FE-50E4-427E-B625-252FAC2DD7C5Q38002994-04EEC2AC-A3B8-4C97-9DB1-C575FD2B7BB8Q38013763-106A4CC5-AB01-472A-AE31-D45CD5E3E5B7Q38044472-35585DD5-D8D1-47CF-9E33-B2B03DC24980Q38227605-5897BBD5-7A5A-4501-AF92-61E0F0BEEBDEQ38376784-406BBBA9-0EEE-43AA-96C0-1499424DEE76Q38739383-C00C402F-02FD-4002-B6AB-890679D5EAA6Q38767186-A08B1024-CFB6-4560-9024-D11BB58CFB8EQ38997467-5E951626-3273-4435-8CFE-C604CE5957C6Q40938357-8981BB5B-D6A3-4E44-9038-21AE6050FF4DQ44897412-C1B85990-6EF9-4628-BD9A-6A6992CEA1CAQ45857037-E7879C92-CD68-400D-AB88-F445DCE36C79Q45867269-715F0C0C-00CC-44B3-94E6-6B4C735E0F63Q45870706-6A615524-4A01-4083-9679-A889FE678120Q45873262-8BA4AA74-20CA-4C27-9C19-4F2560997A53Q45874959-F23C8579-7245-4305-92A8-55C265E7220CQ45886106-945A64DD-74A9-401F-8113-44E6EE678CF9Q45886531-446B85A7-29A0-4580-9375-CF095310171DQ57083979-2B2DF6E5-A50D-4EAF-91BC-0BC614E0A2D6
P2860
Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-utility analysis of Canad ...... ren with severe haemophilia A.
@en
Cost-utility analysis of Canad ...... ren with severe haemophilia A.
@nl
type
label
Cost-utility analysis of Canad ...... ren with severe haemophilia A.
@en
Cost-utility analysis of Canad ...... ren with severe haemophilia A.
@nl
prefLabel
Cost-utility analysis of Canad ...... ren with severe haemophilia A.
@en
Cost-utility analysis of Canad ...... ren with severe haemophilia A.
@nl
P2093
P1433
P1476
Cost-utility analysis of Canad ...... ren with severe haemophilia A.
@en
P2093
P304
P356
10.1111/J.1365-2516.2008.01664.X
P577
2008-04-16T00:00:00Z